ClinicalTrials.gg
CompletedNCT00002133Updated Jun 24, 2005

An Open Study of the Effect of Itraconazole Oral Solution for the Treatment of Fluconazole Refractory Oropharyngeal Candidiasis in HIV-Positive Subjects.

An interventional study of Itraconazole in Candidiasis, Oral and HIV Infections, sponsored by Janssen, LP. Completed at 18 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2005-06-24.

Sponsored by Janssen, LP (part of Johnson & Johnson) · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 26 studies in Candidiasis, Oral with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Candidiasis, Oral · United States.

No phase
12 of 26
none open now
Registered
1st of 26
by date
Lead sponsor
2 of 26
Janssen, LP

Among the 26 studies in Candidiasis, Oral with a site in United States, this one is one of 12 with no phase, and was the 1st registered.

Candidiasis, Oral

48 studies on the registry are indexed under Candidiasis, Oral; 6 are open to participants now.

Browse Candidiasis, Oral studies →

Open to participants now

2 of the 26 studies in Candidiasis, Oral with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 3 Candidiasis, Oral studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Candidiasis, Oral with a site in United States, or all of them as a file.
02

Study summary

To assess the efficacy and safety of itraconazole oral solution in HIV-seropositive patients with oropharyngeal candidiasis that is refractory to fluconazole.

Read the detailed description

Patients receive itraconazole oral solution twice daily. Per 08/15/94 amendment, patients with complete resolution of oropharyngeal candidiasis lesions upon completion of treatment are eligible for maintenance treatment on protocol FDA 236C. Patients who decline maintenance are followed for 6 weeks. Patients who relapse during follow-up are re-treated for 14-28 days; if lesions clear, patients may enter the maintenance protocol.

03

Conditions studied

  • Candidiasis, Oral
  • HIV Infections

Keywords

  • Itraconazole
  • Acquired Immunodeficiency Syndrome
  • AIDS-Related Complex
  • Candidiasis, Oral
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must have:

  • antibody seropositivity or diagnosis of AIDS.
  • Confirmed oropharyngeal candidiasis.
  • Failed fluconazole treatment within the past 14 days.
  • of at least 3 months.
  • NO symptoms of esophageal candidiasis (e.g., dysphagia) unless endoscopic exam of esophagus was performed and fungal esophagitis was not present.
  • NO prior disseminated candidiasis.

Exclusion criteria

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

  • Underlying clinical condition that precludes study completion or places the patient at significant risk.
  • Considered unreliable about following physician's directives.

Concurrent Medication:

Excluded:

  • drugs (approved expanded access drugs are permitted).
  • Rifampin.
  • Rifabutin.
  • Phenobarbital.
  • Phenytoin.
  • Carbamazepine.
  • Terfenadine.
  • Astemizole.

Patients with the following prior conditions are excluded:

  • History of to imidazole or azole compounds.
  • Clinical evidence of significant hepatic disease within the past 2 months.

Prior Medication:

Excluded:

  • Investigational drugs within 1 month prior to study entry (approved expanded access drugs are permitted).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Masking
None (open label)

Interventions

06

Study locations

18 sites
  • Univ of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Univ of Arkansas for Med Sciences
    Little Rock, Arkansas 72205, United States
  • East Bay AIDS Ctr
    Berkeley, California 94705, United States
  • Kaiser Permanente Med Ctr
    San Francisco, California 94115, United States
  • Dr Douglas Ward
    Washington, District of Columbia 20009, United States
  • George Washington Univ Med Ctr
    Washington, District of Columbia 20037, United States
  • Veterans Administration Med Ctr
    Washington, District of Columbia 20422, United States
  • Infectious Diseases Research Clinic / Indiana Univ Hosp
    Indianapolis, Indiana 46202, United States
  • Natl Inst of Allergy & Infect Dis / Cln Ctr
    Bethesda, Maryland 20892, United States
  • Ann Arbor Veterans Administration Med Ctr
    Ann Arbor, Michigan 48105, United States
  • Wayne State Univ / Harper Hosp
    Detroit, Michigan 48201, United States
  • Washington Univ
    St. Louis, Missouri 63108, United States
  • Ohio State Univ Hosp
    Columbus, Ohio 43210, United States
  • Oklahoma City Veterans Administration Med Ctr
    Oklahoma City, Oklahoma 73104, United States
  • Pennsylvania Hosp
    Philadelphia, Pennsylvania 19107, United States
  • Infectious Disease Clinic
    Nashville, Tennessee 37212, United States
  • Audie L Murphy Veterans Administration Hosp
    San Antonio, Texas 78284, United States
  • Univ of Virginia Health Sciences Ctr
    Charlottesville, Virginia 22908, United States
07

References and documents

Publications

  • Moskovitz B, Wu J, Baruch A, Benken C. Long term safety and efficacy of itraconazole oral solution (IS) for treatment of fluconazole refractory oropharyngeal candidiasis (OC) in HIV-positive patients (pts). Conf Retroviruses Opportunistic Infect. 1997 Jan 22-26;4th:124 (abstract no 325)
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00002133
Lead sponsor
Janssen, LP
First posted
Aug 31, 2001
Last update
Jun 24, 2005
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 1996. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Itraconazole

Start the discussion